The CeMM & Angelini Ventures Healthy Lifespan Expansion Initiative
CeMM and Angelini Ventures are joining forces to support CeMM Principal Investigators Laura de Rooij and André Rendeiro in critical lifespan expansion initiatives leveraging a novel academic/entrepreneurial dual-track program. De Rooij and Rendeiro, in collaboration with their teams, will lead an original research program on healthy lifespan expansion. In parallel, they will collaborate on venture creation based on scientific and business insights developed by their work. Venture creation and related business development activities will take place along with scientific research. The expectation is that this double-track initiative will…Read more
Visit of the Italian Ambassador H.E. Stefano Beltrame at CeMM
On 16 March 2023, CeMM was honored to receive the Italian Ambassador H.E. Stefano Beltrame, the First Secretary Valeria Gravagno, and the Scientific Counselor Amedeo Staiano from the Italian Embassy in Austria. We took the opportunity to present CeMM, our infrastructure as well as our research highlights, interests, and achievements.
Our guests were welcomed by CeMM Scientific Director Giulio Superti-Furga, who accompanied them through the building all the way to discover our famous Brain Lounge, where creative ideas are born. It was the perfect place to discover more about our institute and talk to some of our CeMM spin-off chief scientific…Read more
Open Postdoc positions at CeMM
We are recruiting a group of postdocs who are eager to pursue ground-breaking biomedical research, and we will help them to establish themselves as future scientific leaders. This postdoc program is designed to prepare postdoctoral researchers for a successful ERC Starting Grant application or equivalent and for an independent research career in top research organizations in Europe and around the world.
The postdoc program is based at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, one of Europe’s leading centers for basic biomedical research – with clinical translation in mind. Our partners are…Read more
Drug discovery: New method identifies E3-specific degraders for targeted therapies
For many years, the team of Principal Investigator Georg Winter at CeMM has been researching the development of Targeted Protein Degraders: a new generation of drugs that achieve greater therapeutic success through the targeted degradation of harmful, pathogenic proteins. In their current study, published in the Journal of the American Chemical Society (JACS), the researchers present a new method for the identification of molecules that could act as degraders and thus be used as therapeutic drugs.
The latest generation of drugs relies on targeted degradation of damaged or pathogenic proteins. This involves the use of chemical molecules that…Read more
Stem cell transplantation: Processes for the restoration of the immune system discovered
In stem cell transplants, which are used for the treatment of leukaemia, the patient's haematopoietic system is eliminated and replaced by haematopoietic cells from donors. Even though the amount of complications occurring in this process is steadily decreasing due to medical progress, the exact mechanisms for the restoration of the immune system in these patients have not yet been conclusively clarified. Researchers at MedUni Vienna, the CeMM Research Centre for Molecular Medicine of the Austrian Academy of Sciences and the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases have now discovered processes that can contribute to the…Read more
Single-cell sequencing on granulomas opens new therapeutic approaches for sarcoidosis
Granulomas are an accumulation of immune cells in the tissue, often the result of an overactive immune response. Granulomas contribute to several inflammatory systemic diseases such as sarcoidosis, berylliosis, and rheumatoid arthritis. For the first time, scientists at CeMM, the Medical University of Vienna and the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases have thoroughly characterized granulomas in the skin in immense detail. The results provide numerous insights into the composition, structure and signaling pathways of granulomas, providing clues for new therapeutic approaches. The study was published in the journal Immu…Read more
From octopus to elephant: a molecular zoo of epigenetics
Christoph Bock’s team at the CeMM established a catalog of DNA methylation across 580 animal species. These data enabled a detailed dissection of the evolution of epigenetic regulation and the epigenome. The new study, published in Nature Communications, shows that the characteristic DNA methylation signatures of animal genomes are evolutionarily very old, having emerged long before the first mammals. Surprisingly, DNA methylation in starfish and sharks follows a very similar “code” as in orangutans or humans. This epigenetic code may even help protect against cancer – as indicated by DNA methylation patterns in birds, which rarely develop…Read more
Season Greetings 2022
2022 has been a special year for all of us, and we would like to thank our CeMM members and collaborators for their effort and dedication to research.
After 15 years of pioneering work, we wanted to see our achievements, our constant development, our innovations in medicine also in our corporate identity. We unveiled a new corporate design and claim that reflects our CeMM principles and goals to improve healthcare. Because Science is our medicine!
Discover the CeMM Research Report 2021, which has been created as a Research Forte box. Behind every medical treatment and any pharmaceutical pill, no matter how small and simple-looking, there is…Read more
Tackling high-risk leukemia: Austrian Science Fund FWF promotes precision oncology at St. Anna CCRI
The innovative "ExTrAct AML" project, funded by the Austrian Science Fund FWF, goes beyond established frontiers to investigate acute myeloid leukemia (AML) in children and adolescents. Individual patient profiles should provide early information on the causes of disease progression or treatment resistance – and how to take countermeasures in time. In contrast to previous approaches, these profiles not only include comprehensive (epi)genetic signatures of the leukemia cells, but also their dysfunctional signaling pathways and sensitivity to more than 100 drugs – determined by a new and particularly precise method, that examines the effect of…Read more
Blocking DNA production in cancer therapy by targeting POLΘ
In a recent study, researchers from Joanna Loizou’s group from CeMM and the Medical University of Vienna investigated the POLΘ enzyme and the role it plays in DNA repair. Inhibiting POLΘ represents a new approach for developing specific therapies, in particular for patients with BRCA1 mutations. The study, published in Cell Reports, shows for the first time that POLΘ fills the gaps in single-stranded DNA that excessively occur in a BRCA1-deficient genetic background, thus demonstrating its important role in keeping BRCA1 deficient cells alive.
A key gene that is faulty leading to breast and ovarian cancer is BRCA1 (BReast CAncer Gene 1),…Read more